[A25-33] Nirsevimab (prevention of RSV lower respiratory tract disease) – Benefit assessment according to §35a Social Code Book V
Last updated 28.05.2025
Project no.:
A25-33
Commission:
Commission awarded on 18.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
| Project no. | Title | Status |
|---|---|---|
| A24-82 | Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease, 2nd. RSV season) – Benefit assessment according to §35a Social Code Book (SGB) V | Commission completed |
| A24-27 | Nirsevimab (prevention of RSV disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |